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Although core-binding factor acute myeloid leukemia (CBF-AML) is generally considered to be a low-risk
form of AML, the survival rate is still 50% to 60%. To evaluate the effectiveness of autologous stem cell trans-
plantation (ASCT) with a PCR-negative graft we analyzed a series of consecutive CBF-AML patients. Between
1997 and 2006, 18 patients aged\60 years were referred under a diagnosis of CBF-AML. Peripheral blood
stem cells (PBSC) were collected after a second or further course of postremission therapy. When.2.0 
106/kg CD34-positive cells with minimal residual disease (MRD) undetectable by nested polymerase chain
reaction (PCR) had been collected, ASCTwas performed with busulfan, etoposide, and cytarabine combined
with granulocyte colony-stimulating factor. Event-free survival (EFS) and complications of ASCTwere then
assessed. Fourteen of the 18 patients received ASCT. The median observation period was 4.4 years. The
5-year EFS was 93% for ASCT patients, despite the presence of adverse factors. In 8 of 10 patients who
had detectable MRD in the bone marrow before ASCT, MRD became undetectable after ASCT. Neutrophils
recovered promptly within 2 weeks, but platelets recovered relatively slowly. Half of the patients suffered
from varicella zoster virus infection. Although 1 case of myelodysplastic syndrome occurred, there was
no case of relapse. ASCT with a PCR-negative graft was associated with excellent EFS. For patients with
CBF-AML, especially with adverse factors or remnant MRD in the bone marrow, this strategy is the treat-
ment of choice.
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Translocation (8;21) (q22;q22) or inversion (16)
occurs in approximately 7% to 8% of patients with
de novo acute myeloid leukemia (AML) [1]. These
leukemia entities are associated with aberration of
core-binding factors (CBF), which are heterodimeric
transcriptional regulators containing a common
b (CBFb) and 1 of 3 a (CBFa) subunits. Translocation
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doi:10.1016/j.bbmt.2008.08.0122fuses the AML1 (CBFa2) gene located on chromo-
some 21 to the ETO (MTG8) gene located on chro-
mosome 8. The CBFb gene located at 16q22 fuses
with the MYH11 gene located at 16p13. The AML1-
ETO or CBFb-MYH11 fusion protein represses and
alters the function of CBF during normal differentia-
tion [2].
Both cytogenetic groups (referred to as CBF-
AML) have a relatively favorable prognosis compared
with most other forms of adult AML [1,3-5]. In youn-
ger patients, repeated cycles of high-dose cytarabine
(HDAC) therapy can prolong survival [6,7].
Prognostic factors of CBF-AML have been evalu-
ated in several studies. In t(8;21) AML patients, infe-
rior outcome has been associated with a high white
blood cell (WBC) count [8], a low platelet count
[8,9], a highWBC index [10], loss of sex chromosomes
[8], expression of CD56 antigen [11], extramedullary
disease [12], non-White race [9], and older age [9].
In inv(16) AML patients, a high WBC count [13,14],
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sence of the additional aberration of trisomy 22 [8]
have been considered to be adverse factors. In addi-
tion, c-KIT mutations have recently been identified
as adverse factors for CBF-AML [16].
Although opinion about these adverse factors
varies, disease-free survival (DFS) is estimated to be
\50% [8-15] when patients with CBF-AML have at
least 1 adverse factor. In addition, response rate and
survival after first relapse are low and short in t(8;21)
AML [8,9].
The European Group for Bone and Marrow
Transplantation and the Japanese Society of Hemato-
poietic Stem Cell Transplantation have recommended
autologous stem cell transplantation (ASCT) for se-
lected AML patients achieving first complete remis-
sion (CR1) [17,18]. Based on these guidelines, ASCT
has been performed at our center for younger AML
patients with favorable risk other than acute promyelo-
cytic leukemia or with intermediate risk without a
human leukocyte antigen (HLA)-matched sibling. In
addition, we have infused peripheral blood stem cells
(PBSC) in which minimal residual disease (MRD) is
undetectable using a nested polymerase chain reaction
(PCR) (ASCT with a PCR-negative graft).
We have retrospectively analyzed a series of youn-
ger consecutive CBF-AML patients and evaluated
ASCT using a PCR-negative graft.
MATERIALS AND METHODS
Patients
The analysis included all consecutive patients aged
\60 years with CBF-AML diagnosed and treated at
our institution between October 1997 and November
2006. In this survey, CBF-AML was defined by the
presence of either t(8;21)(q22;q22) or inv(16)(p13q22)/
t(16;16)(p13;q22) chromosomal rearrangement, or by
the presence of the AML1-ETO (MTG8) fusion
gene or the presence of the CBFb-MYH11 fusion
gene confirmed by PCR. Although this study was
not a formal clinical trial, all events and information
were systematically recorded and available. This
analysis was approved by our institutional review
board.
Therapy
Induction therapy for younger patients aged\60
years was started with idarubicin (12 mg/m2 days
1-3) and cytarabine (100 mg/m2 days 1-7). After
achievement of complete remission, the patients re-
ceived postremission chemotherapy as follows: first
postremission chemotherapy, idarubicin (12 mg/m2,
days 1-2) and cytarabine (2 g/m2, every 12 hours,
days 1-4); second therapy, enocitabine (200 mg/m2,days 1-7), etoposide (100 mg/m2, days 1-5), daunoru-
bicin (50 mg/m2, days 1-3) and mercaptopurine
(70 mg/m2, days 1-7); third therapy, mitoxantrone
(10 mg/m2, days 1-2), etoposide (100 mg/m2, days
1-4), and cytarabine (1 g/m2, every 12 hours, days
1-4); fourth to seventh therapy, cytarabine (3 g/m2,
every 12 hours, days 1,3,5).
If a patient had neither active infection nor sepsis,
PBSCweremobilized by granulocyte colony-stimulat-
ing factor (G-CSF), and a collection of PBSC was
attempted in the phase of recovery from myelosup-
pression after second or further postremission chemo-
therapy. One cycle of PBSC collection was defined as
a sequential collection course after 1 chemotherapy
course. PBSC collection was repeatedly attempted
within a maximum of 3 cycles. When more than 2.0
 106/kg CD34-positive cells in which MRD was
undetectable by nested PCR had been collected,
ASCT was attempted after a third or further session
of postremission chemotherapy. Although the ideal
doses were .2.0  106/kg CD34-positive cells, in
fact, ASCT was performed when at least 1.5  106/
kg CD34-positive cells were collected after 3 cycles
of PBSC collections had been attempted.
The conditioning regimen for ASCT was G-CSF
combined with BEA [19] as follows: busulfan (4 mg/
kg/day for 4 days as 1 mg/kg four times a day for 16
doses on days 2926), etoposide (20 mg/kg on days
2524), cytarabine (100 mg/m2 on days 21024,
3 g/m2 every 12 hours on days2322), and filgrastim
200 mg/m2 on days 21224). PBSC were adminis-
tered on day 0. Filgrastim (300 mg) was started on
day 1 until recovery of granulocytes. Prophylactic
levofloxacin or tosufloxacin 300 mg/day, fluconazole
200 mg/day, and acyclovir 1000 mg/day were adminis-
tered from day 27 until neutrophils had recovered to
.0.5  109/L.
Minimal Residual Disease Monitoring
We evaluated the bone marrow (BM) and har-
vested PBSC for assessment of MRD. From 2001,
we used quantitative real-time reverse transcriptase
PCR (RQ-PCR) for detection of MRD in BM. Before
2000, MRD in BM was evaluated by fluorescence in
situ hybridization or nested reverse transcriptase
PCR (nested RT-PCR). MRD in PBSC were evalu-
ated by nested RT-PCR.
For PCR, total RNA was extracted from mononu-
clear cells in BM and transcribed to cDNA in accor-
dance with the manufacturer’s instructions. RT-PCR
assay [20-23] was performed by Taqman technology
using the following primers: for AML1/MTG8 chime-
ric mRNA, forward 50.GAG CCA TCA AAA TCA
CAG TGG A .30, reverse 50.ATG AAC TGG
TTC TTG GAG CTC CTT .30, and probe 50
FAM (6-carboxylfluorescein).CAC CTG TGG
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TG.TAMRA (6-carboxy-tetramethyl-rhodamine)
30; for CBFb/MYH11 chimeric mRNA, forward
50.CTC CAA AGA CTG GAT GGT ATG GGC
.30, reverse 50.CTT GGA CTT CTC CAG CTC
ATG G .30, and probe 50 FAM.TCT GGA GTT
TGA TGA GGA GCG AGC CC.TAMRA 30.
Nested RT-PCR was performed in accordance with
previous reports [21-23]. For RQ-PCR, the number
of transcript copies was normalized relative to glycer-
aldehyde 3-phosphate dehydrogenase, and converted
into molecules/mg RNA. The detection threshold of
RQ-PCR was 50 copies/mg RNA and the sensitivity
was 1024. The threshold of nested RT-PCR was 1025.
Mutational Analysis of c-KIT
Mutational analysis of the extracellular (EC) do-
main (exons 8 and 9), transmembrane (TM) domain
(exon 10), juxtamembrane (JM) domain (exon 11),
and the second intracellular kinase (TK) 2 domain
(exons 17 and 18) of the c-KIT gene was performed
with PCR followed by direct sequencing. The geno-
mic DNA from Wright-Giemsa-stained or unstained
blood smears was extracted with a Gentra Puregene
Tissue Kit (Qiagen, Hilden, Germany). TaKaRa LA
Taq DNA polymerase (Takara, Shiga, Japan) was
used to amplify the genes from genomic DNA. PCR
products were purified using the QIAquick PCR
purification kit (Qiagen) and sequenced bidirectionally
using the Big Dye Termination 3.1 kit and the ABI
Prism 310 system (Perkin-Elmer Cetus, Norwalk,
CT). Specific sequences of primers used for PCR
and sequencing are available upon request. To validate
the sequencing results, PCR products were inserted
into the pCR2.1-TOPO vector using a TOPO TA
cloning kit (Invitrogen, Carlsbad, CA). Recombinant
plasmids isolated from 8 to 12 white colonies were
sequenced.
Statistical Analysis
The major indicator of outcome was event-free
survival (EFS), defined as the period from initial diag-
nosis to relapse (failure), secondary malignancy (fail-
ure), death because of any cause (failure), and alive at
last follow-up (censored). Overall survival (OS) was
also assessed, and was defined as the period from initial
diagnosis to death because of any cause (failure), and
alive at last follow-up (censored). Estimations of EFS
and OS distributions were performed by the Kaplan-
Meier method. Comparisons of patient characteristics
were performed by c2 test for categorical variables and
by the Mann-WhitneyU test for continuous variables.
A Cox hazard model was used for univariate analysis of
prognostic factors. Estimates of hazard ratios (HR)
and corresponding 95% confidence intervals (CIs)
were obtained for each of the following variables:gender, age, WBC, hemoglobin, platelets, lactate
dehydrogenase (LDH), percentage of blasts in periph-
eral blood or BM, WBC index, karyotype aberration,
CD56 positivity, and total dose of cytarabine. WBC
index was derived as the product ofWBC and the ratio
of marrow blasts at diagnosis [10]. To assess the impact
on EFS of a cytarabine dosage exceeding 1 g/m2, the
actual cumulative dosage was calculated and entered
as a continuous variable for univariate analysis. For
all analyses, statistical significance was defined as
a 2-sided value of P \ .05. Statistical analyses were
performed with StatView version 5.0.
RESULTS
Patient Characteristics
Between October 1997 and November 2006, 25
patients were diagnosed as having CBF-AML. Of
these patients, 18 were\60 years old and eligible for
ASCT. Sixteen had t(8;21) AML and 2 had inv(16)
AML (Table 1). Fourteen patients actually received
ASCT. The remaining 4 who did not received ASCT
included 2 with relapse and secondary myelodysplasia
during postremission chemotherapy, 1 with poor
mobilization of PBSC, and 1 who withdrew consent
to treatment. The relapsed andMDS patients received
allogeneic transplantation at other hospitals and were
lost to follow-up.
Between patients with and without ASCT, there
were no significant differences in additional chromo-
some aberrations, CD56 positivity or WBC index.
However, patients with ASCT had moderately lower
platelet counts as well as more blasts in their peripheral
blood and BM at diagnosis, and received a lower cu-
mulative dose of cytarabine, although the differences
were not statistically significant.
Survival Analysis
The median period of observation of survivors was
4.4 years. All of 18 patients achieved complete remis-
sion after induction therapy. The estimated 5-year
EFS for these patients and the patients with ASCT
was 83.0% 6 9.0% (6standard error) and 92.9% 6
6.9%, respectively (Figure 1). The estimated 5-year
OS for the 18 patients was 100%, although follow-
up details were lost for relapsed and MDS patients
who later underwent allogeneic transplantation at
other hospitals. Univariate analysis of prognostic fac-
tors for EFS showed that ASCT was the only signifi-
cant factor (HR 12.9 [CIs: 1.05-157, P 5 .045]), and
that age, WBC, cumulative dose of cytarabine,
CD56 positivity, loss of sex chromosomes, and lower
platelet count had no prognostic value for EFS. Anal-
ysis of OS was not done because none of the patients
died.
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Fourteen patients received ASCT using an identi-
cal conditioning regimen and PBSC with undetectable
MRD. The median period from diagnosis to ASCT
was about 9 months (Table 2). A median of 5 chemo-
therapy courses were given before ASCT. Neutrophil
counts recovered to more than 0.5  109/L within
a median period of 13 days (range: 1136 days). Plate-
let counts recovered to .20  109/L without transfu-
sion within a median period of 27.5 days (range:
Table 1. Patient Characteristics and Clinical Features
Total With ASCT
Without
ASCT
P
Value
Number of
patients
18 14 4
Gender
male 15 11 4 *.80
female 3 3 0
Age (years)
median 44 44 51 †.2
range 20–59 20–59 43–53
WBC (x109/L)
median 5.5 5.5 6.8 †.91
range 1.7–82 1.7–82 2.5–37
Hb (g/L)
median 85.5 78 99 †.46
range 38–131 38–131 77–12.6
Plt (x109/L)
median 35 24 58 †.089
range 7.0–101 7.0–101 44–81
LDH (IU/L)
median 661 872 644 †.75
range 245–6090 245–6090 420–1865
PB blast (%)
median 47 49.5 32.8 †.22
range 13–90 24.5–90 18–82.5
BM blast (%)
median 67.3 71.2 61.25 †.24
range 26.4–84.4 26.4–84.4 50.4–64.3
WBC index
Low 5 5 2 *.80
Intermediate 6 6 1
High 3 3 1
Karyotype
t(8;21) 16 *.50
only t(8;21) 7 5 2
-X or -Y 8 7 1
del(9q) 3 2 1
inv(16) 2
only inv(16) 2 2 0
trisomy 22 0 0 0
CD56‡
+ 8 5 3 *.67
2 4 3 1
Extramedullary
involvement
0 0 0
Cumulative
AC (g/m2)
48 (12-114) 48 (12-78) 60 (30-114) †.3
ASCT indicates autologous stem cell transplantation; WBC, white blood
cell; Hb, hemoglobin; plt, platelet; LDH, lactate dehydrogenase; PB, pe-
ripheral blood; BM, bone marrow; cumulative AC, the actual cumulative
dosage of cytarabine exceeding I g/m2; WBC index, WBC x [% of mar-
row blast] low index <2.5, intermeditate index between 2.5 and 20; high
index 20 or more.
P-value was calculated by x2 exact test(*) or U exact test of Mann
Whitney(†). P < .05 was considered as significant value. ‡ CD56 expres-
sion was investigated in 12 of total 18 patients.12217 days) and to.50 109/L within a median pe-
riod of 4 months (range: 15-378 days). Infusion of
more CD34 cells was associated with prompter plate-
let recovery (P 5 .027 for platelets .20  109/L and
P5 .038 for platelets.50 109/L, calculated by Pear-
son’s correlation coefficient). As late adverse events, 5
patients suffered varicella zoster virus (VZV) reactiva-
tion, which was promptly resolved with acyclovir.
These infections occurred at a median of 130 days after
ASCT (range: 85-567 days). Although 1 case of sec-
ondary myelodysplasia was observed after ASCT, no
relapse occurred.
Details of PBSC Collection Among ASCT
Patients
In total, 23 cycles of PBSC collection were per-
formed in 14 patients. A median of 1.85  106/kg
CD34-positive cells were collected in each cycle. Eight
cycles of PBSC collection were performed after the
fourth session of postremission chemotherapy, 4 cycles
after the fifth and sixth sessions, and 3 cycles after
the second and third sessions. In 1 cycle, collections
0
.2
.4
.6
.8
1
0 2 4 6 8 10
with ASCT (N=14)
without ASCT (N=4)
year
Figure 1. Kaplan-Meier curves of EFS of the subgroup of patients with
(n 5 14) and without (n 5 4) autologous stem cell transplantation.
ASCT: autologous stem cell transplantation.
Table 2. Clinical Features of Patients with ASCT
Total number 14 cases
Conditioning regimen Bu+VP16+AraC 14 cases
Median time to stem cell transplantation* 273 days (167–375)*
Median number of prior chemotherapy sessions* 5 times (3–8)*
Median number of cycle of PBSCH* 2 times (1–3)*
Median number of infused CD34 positive cells* 2.6106/kg (1.5–4.4)*
Recovery of neutrophil count (>0.5109/L) 13 days (11–36)*
Recovery of platelet count (>20109/L) 27.5 days (12–217)*
Recovery of platelet count (>50109/L)* 123 days (15–378)*
Median observation duration after transplantation* 4.3 years (1.3–8.9)*
Late adverse events
MDS/sAML 1 case
VZV 5 cases
pneumonia 1 case
meningitis 1 case
PBSCH indicates harvest of peripheral blood stem cell; MDS/sAML,
myelodysplastic syndrome/secondary acute myeloid leukemia.
*Ranges are shown in parentheses.
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CD34 Doses/days of Collection in Each Cycle
Post-remission chemotherapy
Pt 1st 2nd 3rd 4th 5th 6th 7th
Actually infused
CD34 Cell Dose
1 1.0106/kg/2 1.9  106/kg/1 2.9  106/kg
2 1.8  106/kg/2 0.28  106/kg/1 2.0  106/kg
3 0.68  106/kg/3 2.9  106/kg/2 3.4  106/kg
4 2.4  106/kg/1 2.4  106/kg
5 ()1.2  106/kg/2 () 0.62  106/kg/3 1.5  106/kg/4 1.5  106/kg
6 () 4.6  106/kg/1 2.2  106/kg/2 2.2  106/kg
7 3.7  106/kg/4 3.7  106/kg
8 8.3  106/kg/3 2.7  106/kg
9 3.5  106/kg/2 3.5  106/kg
10 4.4  106/kg/2 4.4  106/kg
11 2.9  106/kg/2 2.9  106/kg
12 0.37  106/kg/3 0.88  106/kg/4 0.15  106/kg/1 1.6  106/kg
13 2.4  106/kg/1 1.3  106/kg/2 2.6  106/kg
14 2.0  105/kg/1 2.0  106/kg
Pt indicates patient number; (X) means that MRD was detected in collected peripheral blood stem cells.were performed for median 2 days (range: 14 days)
(Table 3).
The PBSC in 3 cycles (patients 5 and 6) were
inappropriate as grafts because MRD was detected
by nested RT-PCR, and the PBSC were therefore dis-
carded. For collection of PBSC with undetectable
MRD, 1 cycle of PBSC collection was sufficient for
7 patients, and 2 cycles were needed in 5 patients
(Table 3). In the remaining 2 patients, 3 cycles were
performed but no more than 2.0  106/kg CD34-
positive cells could be collected.
MRD in BM was assessed by RT-PCR before che-
motherapy in each of 20 cycles (Table 4). MRD re-
mained in BM in 18 of the investigated 20 cycles.
However, PBSC with undetectable MRD were col-lected in 15 of the 18 cycles. Finally, all 14 patients
received PBSC with undetectable MRD.
MRD Monitoring of ASCT Patients
Table 4 shows the time courses of MRD and the
timing of PBSC collections among ASCT patients.
All of the patients sustained complete remission after
ASCT, and MRD in BM remained at\100 copies/
mgRNA in all 14 patients and became undetectable
by RT-PCR in 12 patients (patients 1-3 and 6-14).
MRD in BM became undetectable by RT-PCR after
ASCT in 8 (patients 1-3, 6, 8, 11, 13, and 14) of 10 pa-
tients (patients 1-6, 8, 11, 13, and 14) whose MRD in
BM before ASCT was detectable by RT-PCR.Table 4. Time Course of Minimal Residual Disease (MRD) among Those with Autologous Stem Cell Transplantation (ASCT)
Postremission Chemotherapy‡ After ASCT
Pt AML type 1st 2nd 3rd 4th 5th 6th 7th ASCT‡ 1 year 2 year 3 year 4 year
1 t(8:21)  5 5 5 5 — — 5 B
2 t(8:21) NA    5  — 5 5 B
3 t(8:21)     5 — — 5 B B
4 t(8:21) N.A    — — —  5 5 5
5 t(8:21) N.A      —  5 5 5
6 t(8:21) N.A   5 5 5 5  5 5 B
7 t(8:21) N.A 5† 5 B B B — B B B B B
8 t(8:21)    — — — —  B B
9 t(8:21) N.A*  N.A* N.A* — — — N.A* B B B B
10 t(8:21) N.A N.A* N.A* 5† — — — N.A* B B B B
11 t(8:21) N.A* N.A* 5† 5† — — — 5† B B B B
12 t(8:21) 5† 5† N.A B — — — B N.A B B B
13 inv(16)  5 5 5 — — — 5 B B B B
14 inv(16) N.A N.A N.A — — — — 5† B B B B
Pt indicates patient number; AML, acute myeloid leukemia; ASCT, autologous stem cell transplantation; —, postremission therapy was not performed;
, MRD was 103-104 copies by RQ-PCR; , MRD was 102-103 copies by RQ-PCR;5, MRD was less than 102 copies by RQ-PCR or detectable by nested
PCR; †, detectable by nested PCR;B, MRD was undetectable by nested PCR or RQ-PCR; N.A, PCR was not performed; *, negative for t(8:21) by FISH;
‡, PCR sample was obtained just before the start of each postremission chemotherapy and conditioning of ASCT;L, Harvest of peripheral blood stem
cells with MRD undetectable by nested PCR;g, Peripheral blood stem cells were not used because MRD was detectable by nested PCR.
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Exon 8 Exon 10 Exon 11 Exon 12 Exon 13 Exon 17 Exon 18 Exon 19 Exon 20
Pt1 normal normal normal normal normal normal normal normal normal
Pt2 normal normal normal normal L813_A814 ins normal normal normal normal
Pt3 normal normal normal normal normal normal normal normal normalInterestingly, in patients 2 and 6, molecular disap-
pearance of AML1/ETO(MTG8) was confirmed by
RT-PCR 2 and 3 years after each ASCT, respectively
(Table 4). In the other 6 patients [patients 1, 3, 8, 11,
13, and 14) MRD was undetectable by RT-PCR 1
year after ASCT.
Analysis of c-KIT Mutations and MRD
c-KIT mutations were analyzed in 3 patients (pa-
tients 1-3). Pt.2 had c-KIT mutations on exon 17,
and the others had no mutations (Table 5). All 3 pa-
tients remained in CR1. AML1/MTG8 chimera was
undetectable by RQ-PCR in all 3 patients.
DISCUSSION
We analyzed the survival of 18 consecutive young
patients with CBF-AML treated between 1997 and
2006 at our center, and revealed that EFS of ASCT
with a PCR-negative graft was 93% with no incidence
of relapse.
Neutrophils recovered promptly within 2 weeks,
but platelets tended to recover more slowly, although
severe hemorrhage was not a complication. After
ASCT, half of the patients suffered late infections, es-
pecially VZV reactivation, at a median of 4 months af-
ter ASCT. Prolonged prophylaxis with acyclovir is
reportedly effective for prevention of VZV reactiva-
tion [24]. The high rate of VZV reactivation in the
present series may have been because of the short
duration of prophylaxis.
Until more than 2.0  106/kg CD34-positive cells
were collected, 1 cycle of PBSC collection was suffi-
cient for half of the patients and 3 cycles were neces-
sary for only 2. This number of collections seems
average in comparison with other studies (median 2
times) [25,26]. Although MRD remained in the BM
in most patients, a PCR-negative graft was obtainable,
except in 3 cycles. This was consistent with other stud-
ies [27,28] in whichMRDwas observed less frequently
in PBSC than in BM. Also in an animal model, leuke-
mic contamination was reportedly not enhanced by
G-CSF mobilization, and a different mechanism for
mobilization of leukemic cells into peripheral blood
was suggested [29].
Previous studies of ASCT in CBF-AML have indi-
cated a survival of about 45% to 66% [8-15], which was
not superior to that achieved with chemotherapy alone[8,9]. Our present result was excellent in comparison
with previous studies. This may have been because of
the characteristics of the patients; our series might in-
clude only patients without adverse factors [8-15] or
c-KIT mutations [16]. In fact, however, those with
ASCT had at least 1 adverse prognostic factor other
than non-White race (Table 1), including a case show-
ing c-KIT mutation of exon 17 (Table 5), which is as-
sociated with a high rate of relapse, although the
number of cases analyzed was too small to allow any
conclusion to be drawn. The main reason for the
good outcome in our series was probably because our
ASCT strategy was based on MRD in PBSC (ASCT
with a PCR-negative graft). A gene-marking study
has suggested that relapse after autologous bone mar-
row transplantation originates from the graft [30]. In
addition, graft contamination of leukemic cells is
associated with rapid relapse and poor prognosis
[31]. We employed grafts in which absence of MRD
was confirmed by nested RT-PCR, and this would
have contributed to the good outcome.
As our analysis was retrospective and involved
a very small population, it might have included variable
bias. Although the present study included truly consec-
utive patients, there might have been an institutional
bias because of the discrepancy in the number of pa-
tients between t(8;21)-AML and inv(16)-AML and be-
cause only 2 patients as yearly average were referred as
having CBF-AML in our institution. In addition, in
general, ASCTwas used for patients with good perfor-
mance status and good control of leukemia, which
would have contributed to the good outcome. How-
ever, the actual OS and EFS for ASCT with a PCR-
negative graft were surprisingly good in our series
(100% and 93%, respectively), and EFS for patients
overall exceeded 80%. Therefore, a prospective trial
will be needed to investigate further confirmation of
ASCT with a PCR-negative graft.
MRD in BM before ASCT was detectable in 10 of
the 12 investigated patients. In 8 of these, MRD in BM
became undetectable by RT-PCR after ASCT. Inter-
estingly, in patients 2 and 6 (Table 4), the AML1/
ETO(MTG8) fusion transcript disappeared 2 and 3
years after each ASCT, respectively, without further
therapy. Although the reason for the late disappear-
ance of MRD was unclear, 1 possibility was an en-
hanced and reconstructed immune response after
ASCT. The myeloablative conditioning regimen
would also have eradicated leukemic stem cells with
1268 Biol Blood Marrow Transplant 14:1262-1269, 2008H. Nakasone et al.self-renewal potential, so that the latent AML1/ETO
fusion transcript may have been correlated with
daughter leukemic cells without self-renewal potential
[27].
The significance ofMRD inCBF-AMLhas not yet
been precisely evaluated because of the persistence of
AML1/ETO and CBFb/MYH11 in long survivors
[13,32,33]. However, a lower frequency of gene fusion,
especially undetectable MRD, is reportedly associated
with long relapse-free survival (RFS) [13,34-36].
Therefore, our results suggest that ASCT with a graft
that is PCR-negative for CBF-AML could be indi-
cated not only for patients with adverse factors but
also those with persistent MRD detectable by RQ-
PCR after postremission therapy.
In conclusion, we have analyzed a series of consec-
utive CBF-AML patients, and found that those with
ASCT had excellent EFS. Even ifMRDwas detectable
in BM, it was possible to harvest a PCR-negative graft.
Our ASCT strategy was based on graft MRD, and this
was thought to have contributed to the excellent EFS
and overcome other adverse factors. A large trial of
ASCT with a PCR-negative graft is warranted for
CBF-AML, especially in patients with adverse factors
or with remnant MRD in BM after postremission
therapy.
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